News Briefing channel feed

EQRx links arms with In­sil­i­co on that two-let­ter buzz­word (AI); De­spite miss in pre­vi­ous­ly treat­ed pa­tients, Ri­bom­ic push­ing eye drug for­ward

4 years ago

Bio­gen, Ei­sai un­veil new da­ta on lecanemab, but ques­tions linger on ARIA-E; Spa­tial bi­ol­o­gy out­fit grabs $33M round

4 years ago

Leg­end re­veals its hold stems from in­suf­fi­cient IND in­fo; Proven­tion re-files BLA af­ter Ju­ly CRL

4 years ago

Rin­voq nabs new ap­proval in sec­ond-line UC; Sen­so­ri­on says its failed drug now works in sub­set analy­sis

4 years ago

Alec­tor presents PhII da­ta on lead de­men­tia drug; Chi­nese on­col­o­gy biotech nets mod­est Se­ries A+

4 years ago

Nat­era shares tum­ble af­ter short-sell­er al­leges de­cep­tive billing prac­tices — and pos­si­bly in­sur­ance fraud

4 years ago

John Maraganore joins up with Pro­QR as strate­gic ad­vi­sor; Servi­er nabs pri­or­i­ty re­view for Tib­so­vo sN­DA

4 years ago

Egg al­ler­gy tri­als halt­ed by Aim­mune; At­las clos­es its 13th fund for $450M

4 years ago

Is­raeli phar­ma touts PhI­II for pre­ma­ture in­fant in­testi­nal mal­a­dy; No­var­tis backs a British biotech's Se­ries B

4 years ago

Ap­pili lands DOD mon­ey for bioter­ror­ism vac­cine; Goldfinch touts new PhII da­ta

4 years ago

Psy­che­delics biotech to en­ter clin­ic in Cana­da; Months af­ter emerg­ing from stealth, Walk­ing Fish clos­es Se­ries A

4 years ago

An­tibi­ot­ic re­sis­tance start­up gets $33M from Boehringer, No­vo; Equi­l­li­um bags a tri-specf­ic

4 years ago

Biofron­tera will yank shares from Nas­daq; In­tel­lia and ONK col­lab­o­rate on can­cer can­di­dates

4 years ago

Bavar­i­an Nordic lands break­through des­ig­na­tion for RSV vac­cine; Ucel­lo clos­es Se­ries A to ad­vance CAR-T ther­a­pies

4 years ago
R&D

EMA ini­ti­ates safe­ty re­view on JAK in­hibitors; Gala­pa­gos woes con­tin­ue as it ter­mi­nates lat­est study 

4 years ago

An­oth­er year, an­oth­er $9M in BAR­DA fund­ing for Medi­Wound; Af­ter PhI­II re­sults, Scynex­is will sub­mit NDA for oral yeast in­fec­tion drug

4 years ago

Bio­Marin lands $110m sale of pri­or­i­ty re­view vouch­er; Hy­bridize li­cens­es out BK virus ther­a­py

4 years ago

New AI start­up launch­es with $40M; Ob­sE­va an­nounces reg­u­la­to­ry holdup for flag­ship drug

4 years ago

Or­chard se­cures re­im­burse­ment for gene ther­a­py; UK fines drug­mak­ers $47M for an­ti­com­pet­i­tive scheme

4 years ago

Macro­Gen­ics ear­marks $580M for ADC tech; Do­mainex, non­prof­it team up on Parkin­son's pro­gram

4 years ago
R&D

4SC pulls plug on do­mati­no­s­tat; Pharm­ing says le­niolis­ib meets both end­points

4 years ago

Af­ter land­ing funds from Roy­al­ty, Cy­to­ki­net­ics an­nounces afi­camten PhII re­sults; Pol­ish CRO Selvi­ta re­struc­tures in search for new growth

4 years ago

Capri­cor gets up to $735M for Duchenne drug's US rights; PCI Biotech ends bile duct can­cer clin­i­cal tri­al

4 years ago

BeiGene/No­var­tis tout new PD-1 da­ta; No­var­tis plans down­siz­ing in Tokyo

4 years ago
First page Previous page 23242526272829 Next page Last page
A service from the Financial Times